At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled Crossover Study to Evaluate the Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With Painful Diabetic Neuropathy and Good Pain Reporting Ability
In Brief
A Phase 2 clinical trial evaluating AZD5213 + pregabalin, Placebo, and 1 other intervention for Diabetic Neuropathy, Painful; Diabetic Neuropathies. Completed, enrolled 150 participants across 9 sites.
Detailed Summary
This is a 2-part study. In Part 1 of the study, subjects will undergo a pain reporting training program in which a painful stimulus will be applied to the subject's hand, and the subjects will be asked to report how painful the stimulus is. Over the course of the pain training sessions, feedback will be provided to the subject about how accurately they are reporting their degree of pain, relative to the amount of pressure stimulus applied to evoke pain. Those subjects who have adequate pain reporting ability will be asked to continue into Part 2 of the study in which 3 different blinded study drugs will be administered to each subject, in a crossover design to compare whether or not the study drugs improve pain associated with diabetic neuropathy.
Study Details
Timeline
Interventions
Double blind Investigational drug AZD5213 (capsules) given in combination with pregabalin (capsules)
Double blind placebo capsules to match AZD5213 and pregabalin
Double blind pregabalin capsules to match AZD5213 and placebo